The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
18 06 2021
Historique:
received: 28 05 2020
revised: 26 09 2020
pubmed: 1 12 2020
medline: 20 8 2021
entrez: 30 11 2020
Statut: ppublish

Résumé

To describe the association between change in subchondral bone marrow lesions (BMLs) and change in tibiofemoral cartilage volume and knee symptoms in patients with symptomatic knee OA. In total, 251 participants (mean 61.7 years, 51% female) were included. Tibiofemoral cartilage volume was measured at baseline and 24 months, and BML size at baseline, 6 and 24 months. Knee pain and function scores were evaluated at baseline, 6 and 24 months. Change in total and compartment-specific BML size was categorized according to the Least Significance Criterion. Linear mixed-effects models were used to evaluate the associations of change in BMLs over 6 and 24 months with change in cartilage volume over 24 months and knee symptoms over 6 and 24 months. Total BML size enlarged in 26% of participants, regressed in 31% and remained stable in 43% over 24 months. Compared with stable BMLs in the same compartment, enlarging BMLs over 24 months were associated with greater cartilage loss (difference: -53.0mm3, 95% CI: -100.0, -6.0), and regressing BMLs were not significantly associated with reduced cartilage loss (difference: 32.4mm3, 95% CI: -8.6, 73.3) over 24 months. Neither enlargement nor regression of total BML size over 6 and 24 months was associated with change in knee pain and function over the same time intervals. In subjects with symptomatic knee osteoarthritis and BMLs, enlarging BMLs may lead to greater cartilage loss but regressing lesions are not associated with reduced cartilage loss while neither is associated with change in knee symptoms.

Identifiants

pubmed: 33253381
pii: 6012794
doi: 10.1093/rheumatology/keaa716
doi:

Substances chimiques

Bone Density Conservation Agents 0
Glucocorticoids 0
Zoledronic Acid 6XC1PAD3KF
Methylprednisolone X4W7ZR7023

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2791-2800

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Guoqi Cai (G)

Department of Endocrinology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Menzies Institute for Medical Research, University of Tasmania, TAS, Hobart, Australia.

Dawn Aitken (D)

Menzies Institute for Medical Research, University of Tasmania, TAS, Hobart, Australia.

Laura L Laslett (LL)

Menzies Institute for Medical Research, University of Tasmania, TAS, Hobart, Australia.

Catherine Hill (C)

Department of Rheumatology, The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia.

Anita E Wluka (AE)

Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia.

Lyn March (L)

Institute of Bone and Joint Research, The University of Sydney, Royal North Shore Hospital, Sydney, Australia.

Flavia Cicuttini (F)

Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia.

Jean-Pierre Pelletier (JP)

Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.

Johanne Martel-Pelletier (J)

Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.

Graeme Jones (G)

Menzies Institute for Medical Research, University of Tasmania, TAS, Hobart, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH